Leupeptin
Also known as: Ac-Leu-Leu-Arg-al, Acetyl-leupeptin, Leupeptin, Leupeptin hemisulfate, N-Acetyl-L-leucyl-L-leucyl-L-argininal, N‑acetyl‑L‑leucyl‑L‑leucyl‑L‑argininal
Source Leupeptin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Leupeptin is a peptide aldehyde that inhibits a range of serine and cysteine proteases. In research it is employed to block proteolytic degradation of biomolecules, to probe protease‑dependent activation pathways, and to improve the stability of peptide drugs such as insulin in experimental formulations.
Mechanism of Action
Leupeptin binds covalently to the active‑site serine or cysteine residues of proteases, forming a reversible hemi‑acetal that blocks substrate access. It potently inhibits calpain, cathepsin B, and other lysosomal cysteine proteases, as well as some serine proteases involved in the conversion of procathepsin D to its mature form. By preventing proteolysis, leupeptin stabilizes proteins and interferes with protease‑driven cellular processes.
What the Research Shows
The literature reports leupeptin used as an enzyme‑inhibitor adjunct in oral insulin formulations to reduce enzymatic breakdown in the gut. It blocks a second protease required for conversion of procathepsin D to active cathepsin D, indicating a role in lysosomal enzyme maturation. In muscle studies, leupeptin (alongside E‑64) modulates calpain activity and influences protein turnover in diseased muscle. Analogs lacking charged groups have been shown to penetrate cells and inhibit intracellular calpain, aiding studies of platelet activation. In lysosome‑biogenesis experiments, leupeptin preferentially affected lysosomal compartments without halting endosomal progression, supporting its utility in dissecting organelle dynamics.
Reported Benefits
Leupeptin provides a reliable tool for protecting peptide therapeutics from proteolysis in experimental delivery systems, notably oral insulin. Its broad inhibition of cysteine and serine proteases enables detailed investigation of protease‑dependent pathways such as cathepsin D activation and calpain‑mediated cellular events. Cell‑penetrating analogs expand its utility to intracellular studies, facilitating functional assays of calpain activity.
Limitations of the Evidence
Evidence for leupeptin’s effects is confined to in vitro assays and animal models; no clinical trials or regulatory approvals exist. Its inhibition is not highly selective, potentially affecting multiple proteases and altering normal protein turnover. Reports on lysosomal biogenesis show mixed outcomes, and its impact on lipofuscin formation suggests possible unintended accumulation of undegraded material. Consequently, translational relevance remains uncertain.
Safety Considerations
Leupeptin is not approved for human therapeutic use and is employed only in research settings. Off‑target protease inhibition may disrupt normal cellular degradation pathways, leading to accumulation of protein aggregates. Animal studies have used intraperitoneal administration; no human safety data are available. Caution is advised when interpreting results, and appropriate biosafety measures should be followed in laboratory handling.
How It Is Administered
Leupeptin is typically applied in vitro as a soluble inhibitor added to cell culture or enzyme assays. In animal research, it has been administered via intraperitoneal injection. Formulations are usually aqueous solutions of the peptide aldehyde; no oral or systemic formulations for human use are reported.
Routes of Administration
Goals & Uses
- Experimental neuroprotection modelPreclinical ResearchLow
- Autophagy researchResearch ToolHigh
- Cathepsin inhibitionResearch ToolHigh
- Calpain inhibitionResearch ToolHigh
- Protease inhibition in cell lysatesResearch/biochemistryHigh
Contraindications
- Human therapeutic useRegulatory/safetyHigh
Adverse Effects
- Cytotoxicity at high concentrationsIn Vitro ToxicityUncommon
- Non-specific protease inhibitionOff Target EffectCommon
Drug Interactions
- E-64 / E64dLow
- PMSF (phenylmethylsulfonyl fluoride)Low
Population Constraints
- All human populationsGeneralAbsolute
Regulatory Status
- European UnionUnapprovedNo EMA approval; available only as a research chemical.
- United StatesUnapprovedResearch reagent only; no FDA approval or IND filing on record.
- United KingdomUnapprovedNo MHRA approval; research use only.
Not approved for clinical use; classified as a research chemical.
Evidence & Sources
- Journal ArticleModerateVerma A, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateRicho G, Conner GE1991-01-01T00:00:00.000000Z
- Journal ArticleModerateHarman D1989-01-01T00:00:00.000000Z
- Journal ArticleModerateObinata T, et al.1981-01-01T00:00:00.000000Z
- Journal ArticleModerateMehdi S1991-01-01T00:00:00.000000Z
- Journal ArticleModerateMorales CR, Zhao Q, Lefrancois S1999-01-01T00:00:00.000000Z
Frequently Asked Questions
Can leupeptin be used to treat diseases in humans?
No. Leupeptin is a research‑grade protease inhibitor with no regulatory approval for clinical use. All reported applications are experimental and confined to laboratory studies.
How does leupeptin improve oral insulin delivery?
In experimental formulations, leupeptin is added to inhibit digestive proteases in the gastrointestinal tract, thereby reducing enzymatic degradation of insulin and enhancing its stability before absorption.
Why are cell‑penetrating leupeptin analogs important?
Standard leupeptin is charged and poorly crosses cell membranes. Modified analogs lacking charged groups can enter cells and inhibit intracellular calpain, allowing researchers to study calpain‑dependent processes that were previously inaccessible.
Does leupeptin affect lysosome formation?
Studies using leupeptin together with lysosomotropic agents suggest it preferentially influences lysosomal compartments without halting endosomal progression, indicating a selective effect on lysosome dynamics in cultured cells.
What are the main safety concerns when using leupeptin in the lab?
Because leupeptin broadly inhibits proteases, it can interfere with normal protein turnover and lead to accumulation of undegraded proteins. Proper protective equipment and waste disposal are recommended to avoid accidental exposure.
What is Leupeptin?
Leupeptin is a peptide aldehyde that inhibits a range of serine and cysteine proteases. In research it is employed to block proteolytic degradation of biomolecules, to probe protease‑dependent activation pathways, and to improve the stability of peptide drugs such as insulin in experimental formulations.
What is Leupeptin used for?
Leupeptin is educationally associated with: Experimental neuroprotection model, Autophagy research, Cathepsin inhibition, Calpain inhibition, Protease inhibition in cell lysates. Educational only — not medical advice.
How is Leupeptin administered?
Recorded routes of administration: In Vitro, Intraperitoneal.
What are the potential side effects of Leupeptin?
Reported adverse effects include: Cytotoxicity at high concentrations, Non-specific protease inhibition. This list is not exhaustive — consult a qualified clinician.
Who should avoid Leupeptin?
Recorded contraindications: Human therapeutic use. Consult a qualified clinician before use.